Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials

Opinion
Video

Hans Lee, MD, discusses recent updates presented at ASCO 2024 surrounding cilta-cel CAR T-cell therapy in relapsed/refractory multiple myeloma.

Video content above is prompted by the following questions:

  • Review the recent updates surrounding CAR T-cell therapy in R/R MM:
    • CARTITUDE-4 subgroup analysis
    • CARTITUDE-2 cohort A expansion subgroup
    • CARTITUDE-2 cohort D
  • What is the rationale for using CAR T-cell therapy in patients with R/R MM?
Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
4 experts in this video
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
4 experts in this video
Related Content
More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

Tim Cortese
July 30th 2025
Article

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 24th 2025
Article

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.